F59 Huntington’s disease young adult study (HD-YAS)

Paul Zeun, J. Lowe, K. Osborne-Crowley, C. O’Callaghan, E. Johnson, S. Gregory, A. Nair, Kate Fayer, F. B. Rodrigues, C. Estévez-Fraga, E. Wild, Gary Zhang, C. Sampaio, T. Robbins, G. Rees, R. Scahill, B. Sahakian, S. Tabrizi
{"title":"F59 Huntington’s disease young adult study (HD-YAS)","authors":"Paul Zeun, J. Lowe, K. Osborne-Crowley, C. O’Callaghan, E. Johnson, S. Gregory, A. Nair, Kate Fayer, F. B. Rodrigues, C. Estévez-Fraga, E. Wild, Gary Zhang, C. Sampaio, T. Robbins, G. Rees, R. Scahill, B. Sahakian, S. Tabrizi","doi":"10.1136/JNNP-2018-EHDN.160","DOIUrl":null,"url":null,"abstract":"HD-YAS will study a cohort of young adult HD Gene Expansion Carriers (HDGEC) decades before expected symptom onset to characterize the very earliest signs of disease-related brain changes and identify whether there is any identifiable early functional impairment. Currently there is no detailed characterization of such a young adult HDGEC cohort and this represents the earliest time point after predictive genetic testing in which to gain disease insights. HD-YAS will be important in determining the earliest potential time window for therapeutic intervention. HD-YAS will recruit 120 participants-60 premanifest HDGECs and 60 gene negative or family controls-and will use a cross-sectional comparison with one visit per participant to assess the earliest time-point at which neurodegeneration can be detected. Participants will undergo 3T Volumetric MRI, rsfMRI and task fMRI, NODDI, and cognitive assessments including the CANTAB and EMOTICOM batteries, and biosamples such as CSF, blood and DNA will be collected to investigate biomarkers. Participants will be 18–40 years old and at-risk individuals must have a predictive genetic test; either carry the HD gene (gene-carrier) or not carry the HD gene (control). Individuals must not show any clinical symptoms of HD, have a disease burden score of ≤240, and must be willing and able to comply with the study visit and study procedures. HD-YAS began in August 2017 and is expected to complete by February 2019. HD-YAS collaborates with Enroll-HD, UK clinical genetics services and HD charity groups to identify potentially eligible participants throughout the UK. HD-YAS is funded by Wellcome, with CSF collection funded by CHDI. HD-YAS investigators – Participant Identification Site Investigators; Dr Oliver Quarrell, Dr Nayana Lahiri, Dr Andrea Nemeth, Dr Mary Porteous, Dr Elisabeth Rosser, Dr David Craufurd, Dr Rhona MacLeod, Dr Deborah Ruddy, Dr Roger Barker, Dr Simon Holden, Dr Hugh Rickards, Dr Anne Rosser, Dr Emma Hobson, Prof Angus Clarke, Dr Katherine Lachlan, Dr Reza Kiani, Dr Timothy Harrower. Thank you to the HDA, HDYO, SHA.","PeriodicalId":7013,"journal":{"name":"A32. ASTHMA: CLINICAL STUDIES II","volume":"74 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"A32. ASTHMA: CLINICAL STUDIES II","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/JNNP-2018-EHDN.160","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

HD-YAS will study a cohort of young adult HD Gene Expansion Carriers (HDGEC) decades before expected symptom onset to characterize the very earliest signs of disease-related brain changes and identify whether there is any identifiable early functional impairment. Currently there is no detailed characterization of such a young adult HDGEC cohort and this represents the earliest time point after predictive genetic testing in which to gain disease insights. HD-YAS will be important in determining the earliest potential time window for therapeutic intervention. HD-YAS will recruit 120 participants-60 premanifest HDGECs and 60 gene negative or family controls-and will use a cross-sectional comparison with one visit per participant to assess the earliest time-point at which neurodegeneration can be detected. Participants will undergo 3T Volumetric MRI, rsfMRI and task fMRI, NODDI, and cognitive assessments including the CANTAB and EMOTICOM batteries, and biosamples such as CSF, blood and DNA will be collected to investigate biomarkers. Participants will be 18–40 years old and at-risk individuals must have a predictive genetic test; either carry the HD gene (gene-carrier) or not carry the HD gene (control). Individuals must not show any clinical symptoms of HD, have a disease burden score of ≤240, and must be willing and able to comply with the study visit and study procedures. HD-YAS began in August 2017 and is expected to complete by February 2019. HD-YAS collaborates with Enroll-HD, UK clinical genetics services and HD charity groups to identify potentially eligible participants throughout the UK. HD-YAS is funded by Wellcome, with CSF collection funded by CHDI. HD-YAS investigators – Participant Identification Site Investigators; Dr Oliver Quarrell, Dr Nayana Lahiri, Dr Andrea Nemeth, Dr Mary Porteous, Dr Elisabeth Rosser, Dr David Craufurd, Dr Rhona MacLeod, Dr Deborah Ruddy, Dr Roger Barker, Dr Simon Holden, Dr Hugh Rickards, Dr Anne Rosser, Dr Emma Hobson, Prof Angus Clarke, Dr Katherine Lachlan, Dr Reza Kiani, Dr Timothy Harrower. Thank you to the HDA, HDYO, SHA.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
F59亨廷顿病青年成人研究(HD-YAS)
HD- yas将研究一组年轻成年HD基因扩增携带者(HDGEC),在预期症状发作前几十年,以表征疾病相关大脑变化的最早迹象,并确定是否存在任何可识别的早期功能损伤。目前还没有这样一个年轻成人HDGEC队列的详细特征,这代表了预测性基因检测后获得疾病见解的最早时间点。HD-YAS对于确定治疗干预的最早潜在时间窗非常重要。HD-YAS将招募120名参与者——60名预先表现的hdgec和60名基因阴性或家族对照者——将使用横断比较,每位参与者一次访问,以评估可以检测到神经退行性变的最早时间点。参与者将接受3T体积MRI、rsfMRI和任务fMRI、NODDI和认知评估,包括CANTAB和EMOTICOM电池,并收集脑脊液、血液和DNA等生物样本以调查生物标志物。参与者将在18-40岁之间,高危人群必须进行预测性基因测试;要么携带HD基因(基因携带者),要么不携带HD基因(对照组)。受试者必须没有HD的任何临床症状,疾病负担评分≤240,并且必须愿意并能够遵守研究访问和研究程序。HD-YAS于2017年8月开始,预计将于2019年2月完成。HD- yas与Enroll-HD,英国临床遗传学服务和HD慈善团体合作,以确定整个英国潜在的合格参与者。HD-YAS由惠康资助,脑脊液收集由中国发展研究院资助。HD-YAS调查员-参与者识别现场调查员;Oliver Quarrell博士、Nayana Lahiri博士、Andrea Nemeth博士、Mary Porteous博士、Elisabeth Rosser博士、David crawford博士、Rhona MacLeod博士、Deborah Ruddy博士、Roger Barker博士、Simon Holden博士、Hugh Rickards博士、Anne Rosser博士、Emma Hobson博士、Angus Clarke教授、Katherine Lachlan博士、Reza Kiani博士、Timothy Harrower博士。感谢HDA, HDYO, SHA。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A New Trend in Sensitization to Cockroach Allergen a Cross-Sectional Study of Indoor Allergens and Food Allergens in the Inland Region of Southwest China Self-Administration of Mepolizumab Liquid Using a Single-Use Prefilled Autoinjector Nationwide Questionnaire-Based Survey on the Safety of Bronchial Thermoplasty for Severe Asthma Patients in Japan Asthma and Fixed Airflow Obstruction: Long-Term Trajectories Reveal Distinct Endotypes Determination of Cut-Off Value of Th2 Markers for Prediction of Future Exacerbation in Severe Asthma: An Analysis from the Hokkaido Severe Asthma Cohort Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1